AAPA Members, login to view FREE Full Text for all articles. Not a member? Join today!

Institutional members access full text with Ovid®

Share this article on:

What are extended-spectrum beta-lactamases?

Sutton, S. Scott PharmD, BCPS

Journal of the American Academy of Physician Assistants: March 2014 - Volume 27 - Issue 3 - p 14–17
doi: 10.1097/01.JAA.0000443810.42907.ec
Pharmacology Consult

ABSTRACT The emergence and spread of extended-spectrum beta-lactamases (ESBLs) in Gram-negative bacteria pose important challenges for clinicians, as management options for these organisms are limited. The emergence of ESBL-producing Gram-negative bacteria is one of the most significant epidemiologic changes in infectious diseases during recent years. Failure to treat with an antibiotic active against ESBL-producing organisms is associated with increased patient morbidity and mortality. Carbapenems are considered the primary antibacterials for infections caused by ESBL-producing organisms but their overuse poses significant cause for concern.

S. Scott Sutton is an associate professor at the University of South Carolina's College of Pharmacy, and a clinical pharmacist in medicine, infectious diseases, and research at Dorn VA Medical Center, both in Columbia, S.C. The author has disclosed no potential conflicts of interest, financial or otherwise.

Mary Lou Brubaker, PharmD, PA-C, department editor

© 2014 American Academy of Physician Assistants.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website